Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05424523 · ClinicalTrials.gov registry record
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 200
- Enrollment target
NCT05424523: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05424523 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05424523 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice.
Primary Outcome
The responders were defined as patients with: 1. Investigator's Global Evaluation of Treatment Effectiveness (GETE) are Excellent or Good; or 2. C-ACT2 improvement ≥3 points before and after omalizumab treatment
Interventions
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2021-06-28 |
What the finished NCT05424523 record still lists
NCT05424523 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT05424523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05424523 about?
NCT05424523 is a clinical study titled "Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.". The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice.
What is the current status of trial NCT05424523?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2021-02-25. Estimated completion is 2021-06-28.
What interventions are being tested in trial NCT05424523?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT05424523?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI